This is an early access version, the complete PDF, HTML, and XML versions will be available soon.
Open AccessArticle
Bicomponent Cutaneous Cell Therapy for Early Burn Care: Manufacturing Homogeneity and Epidermis-Structuring Functions of Clinical Grade FE002-SK2 Allogeneic Dermal Progenitor Fibroblasts
by
Xi Chen
Xi Chen 1
,
Nathalie Hirt-Burri
Nathalie Hirt-Burri 1
,
Corinne Scaletta
Corinne Scaletta 1
,
Alexis E. Laurent
Alexis E. Laurent 1,2,*,†
and
Lee Ann Applegate
Lee Ann Applegate 1,3,4,*,†
1
Regenerative Therapy Unit, Lausanne University Hospital, University of Lausanne, CH-1066 Epalinges, Switzerland
2
Manufacturing Department, TEC-PHARMA SA, CH-1038 Bercher, Switzerland
3
Center for Applied Biotechnology and Molecular Medicine, University of Zurich, CH-8057 Zurich, Switzerland
4
Oxford OSCAR Suzhou Center, Oxford University, Suzhou 215123, China
*
Authors to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Pharmaceutics 2025, 17(6), 692; https://doi.org/10.3390/pharmaceutics17060692 (registering DOI)
Submission received: 8 April 2025
/
Revised: 20 May 2025
/
Accepted: 20 May 2025
/
Published: 24 May 2025
Abstract
Background: The extracellular matrix (ECM), primarily composed of collagen and elastin synthesized by dermal fibroblasts, is critical for mesenchymal tissue integrity. Fibroblast phenotypes vary significantly with the anatomical location and developmental stage. Fetal skin, particularly prior to 14 weeks of gestation, exhibits a simplified structure compared to adult skin, characterized by a thin, loose dermal matrix and a single-layered epithelium. Objectives: This study aimed to characterize and functionally compare homogenous progenitor fetal fibroblast (PFF) populations derived from 14-week-old fetal skin with fibroblasts isolated from adult burn patients. Methods: We evaluated the proliferative capacity, collagen synthesis, and differentiation potential (adipogenesis and osteogenesis) of PFF and adult burn patient fibroblasts. Furthermore, we assessed their ability to support skin regeneration using a de-epidermized dermis (DED) model seeded with both PFF and patient-derived keratinocytes. The stability of PFF characteristics was monitored across multiple passages (P5–P12). Results: PFF demonstrated a 2–4-fold increase in proliferation rate and a 30–50% enhancement in collagen production in vitro compared to adult fibroblasts. Notably, PFF exhibited a consistent lack of adipogenic and osteogenic differentiation, an attribute distinct from adult fibroblasts. In the DED model, PFF, even at a low fibroblast-to-keratinocyte ratio (1:5), effectively facilitated the formation of well-organized skin structures, including rete ridges, surpassing the performance of adult fibroblasts and adipose-derived cells. These properties remained stable over multiple passages. Conclusions: The unique attributes of PFF, likely attributable to the simplified microenvironment (i.e., collagen organization) of developing fetal tissue, positions them as a promising source for cell-based therapies. Their inherent high collagen synthesis capacity is particularly advantageous for wound healing applications. Consequently, PFF represent a consistent and readily available resource for developing “off-the-freezer” cutaneous cell therapies, potentially enabling accelerated and improved treatment of severe burn injuries.
Share and Cite
MDPI and ACS Style
Chen, X.; Hirt-Burri, N.; Scaletta, C.; Laurent, A.E.; Applegate, L.A.
Bicomponent Cutaneous Cell Therapy for Early Burn Care: Manufacturing Homogeneity and Epidermis-Structuring Functions of Clinical Grade FE002-SK2 Allogeneic Dermal Progenitor Fibroblasts. Pharmaceutics 2025, 17, 692.
https://doi.org/10.3390/pharmaceutics17060692
AMA Style
Chen X, Hirt-Burri N, Scaletta C, Laurent AE, Applegate LA.
Bicomponent Cutaneous Cell Therapy for Early Burn Care: Manufacturing Homogeneity and Epidermis-Structuring Functions of Clinical Grade FE002-SK2 Allogeneic Dermal Progenitor Fibroblasts. Pharmaceutics. 2025; 17(6):692.
https://doi.org/10.3390/pharmaceutics17060692
Chicago/Turabian Style
Chen, Xi, Nathalie Hirt-Burri, Corinne Scaletta, Alexis E. Laurent, and Lee Ann Applegate.
2025. "Bicomponent Cutaneous Cell Therapy for Early Burn Care: Manufacturing Homogeneity and Epidermis-Structuring Functions of Clinical Grade FE002-SK2 Allogeneic Dermal Progenitor Fibroblasts" Pharmaceutics 17, no. 6: 692.
https://doi.org/10.3390/pharmaceutics17060692
APA Style
Chen, X., Hirt-Burri, N., Scaletta, C., Laurent, A. E., & Applegate, L. A.
(2025). Bicomponent Cutaneous Cell Therapy for Early Burn Care: Manufacturing Homogeneity and Epidermis-Structuring Functions of Clinical Grade FE002-SK2 Allogeneic Dermal Progenitor Fibroblasts. Pharmaceutics, 17(6), 692.
https://doi.org/10.3390/pharmaceutics17060692
Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details
here.
Article Metrics
Article Access Statistics
For more information on the journal statistics, click
here.
Multiple requests from the same IP address are counted as one view.